| [1] |
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6 |
| [2] |
AMET S, BRONOWICKI JP, THABUT D, et al. Prevalence of renal abnormalities in chronic HBV infection: The HARPE study[J]. Liver Int, 2015, 35(1): 148-155. DOI: 10.1111/liv.12480 |
| [3] |
XU MD F, WANG MD C, SHI MD X, et al. Resolution of HBV infection occurs sooner than recovery of renal disease in adult serum HBsAg-negative HBV-associated glomerulonephritis[J]. J Med Virol, 2018, 90(9): 1503-1507. DOI: 10.1002/jmv.25211 |
| [4] |
VERRIER ER, COLPITTS CC, BACH C, et al. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses[J]. Hepatology, 2016, 63(1): 35-48. DOI: 10.1002/hep.28013 |
| [5] |
MITRA B, THAPA RJ, GUO H, et al. Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B[J]. Antiviral Res, 2018, 158: 185-198. DOI: 10.1016/j.antiviral.2018.08.014 |
| [6] |
YANG F, WU L, XU W, et al. Diverse effects of the NTCP p. Ser267Phe Variant on disease progression during chronic HBV infection and on HBV preS1 variability[J]. Front Cell Infect Microbiol, 2019, 9: 18. DOI: 10.3389/fcimb.2019.00018 |
| [7] |
MEREDITH LW, HU K, CHENG X, et al. Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors[J]. J Gen Virol, 2016, 97(1): 121-127. DOI: 10.1099/jgv.0.000317 |
| [8] |
KO HL, LAM TH, NG H, et al. Identification of Slug and SOX7 as transcriptional repressors binding to the hepatitis B virus core promoter[J]. J Hepatol, 2017.[Online ahead of print]
|
| [9] |
FERDEK PE, JAKUBOWSKA MA, GERASIMENKO JV, et al. Bile acids induce necrosis in pancreatic stellate cells dependent on calcium entry and sodium-driven bile uptake[J]. J Physiol, 2016, 594(21): 6147-6164. DOI: 10.1113/JP272774 |
| [10] |
LAU HH, NG N, LOO L, et al. The molecular functions of hepatocyte nuclear factors - In and beyond the liver[J]. J Hepatol, 2018, 68(5): 1033-1048. DOI: 10.1016/j.jhep.2017.11.026 |
| [11] |
YANG X, CAI W, SUN X, et al. Defined host factors support HBV infection in non-hepatic 293T cells[J]. J Cell Mol Med, 2020, 24(4): 2507-2518. DOI: 10.1111/jcmm.14944 |
| [12] |
HERRSCHER C, PASTOR F, BURLAUD-GAILLARD J, et al. Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis[J]. Cell Microbiol, 2020, 22(8): e13205.
|
| [13] |
IWAMOTO M, SASO W, SUGIYAMA R, et al. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization[J]. Proc Natl Acad Sci U S A, 2019, 116(17): 8487-8492. DOI: 10.1073/pnas.1811064116 |
| [14] |
OCHI M, OTSUKA M, MARUYAMA R, et al. HBx increases EGFR expression by inhibiting miR129-5p function[J]. Biochem Biophys Res Commun, 2020, 529(2): 198-203. DOI: 10.1016/j.bbrc.2020.06.018 |
| [15] |
|
| [16] |
LI H, SHAO F, QIAN B, et al. Upregulation of HER2 in tubular epithelial cell drives fibroblast activation and renal fibrosis[J]. Kidney Int, 2019, 96(3): 674-688. DOI: 10.1016/j.kint.2019.04.012 |
| [17] |
HERRSCHER C, ROINGEARD P, BLANCHARD E. Hepatitis B virus entry into cells[J]. Cells-Basel, 2020, 9(6): 1486. DOI: 10.3390/cells9061486 |
| [18] |
IWAMOTO M, SASO W, NISHIOKA K, et al. The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network[J]. J Biol Chem, 2020, 295(3): 800-807. DOI: 10.1016/S0021-9258(17)49936-4 |
| [19] |
HU Q, ZHANG F, DUAN L, et al. E-cadherin plays a role in hepatitis B virus entry through affecting glycosylated sodium-taurocholate cotransporting polypeptide distribution[J]. Front Cell Infect Microbiol, 2020, 10: 74. DOI: 10.3389/fcimb.2020.00074 |
| [20] |
WANG X, WANG L, ZHU N, et al. Hepatitis B virus X protein modulates renal tubular epithelial cell-induced T-cell and macrophage responses[J]. Immunol Cell Biol, 2016, 94(3): 266-273. DOI: 10.1038/icb.2015.85 |
| [21] |
HOCHANE M, RAISON D, COQUARD C, et al. Parathyroid hormone-related protein modulates inflammation in mouse mesangial cells and blunts apoptosis by enhancing COX-2 expression[J]. Am J Physiol Cell Physiol, 2018, 314(2): C242-C253. DOI: 10.1152/ajpcell.00018.2017 |
| [22] |
MASOLA V, CARRARO A, GRANATA S, et al. In vitro effects of interleukin (IL)-1 beta inhibition on the epithelial-to-mesenchymal transition (EMT) of renal tubular and hepatic stellate cells[J]. J Transl Med, 2019, 17(1): 12. DOI: 10.1186/s12967-019-1770-1 |
| [23] |
WANG L, YE Z, LIANG H, et al. The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication[J]. Am J Transl Res, 2016, 8(3): 1593-1600. http://europepmc.org/abstract/MED/26807867 |
| [24] |
ALLWEISS L, DANDRI M. The role of cccDNA in HBV maintenance[J]. Viruses, 2017, 9(6): 156. DOI: 10.3390/v9060156 |
| [25] |
|
| [26] |
PRESCOTT NA, BRAM Y, SCHWARTZ RE, et al. Targeting hepatitis B virus covalently closed circular DNA and hepatitis B virus x protein: Recent advances and new approaches[J]. ACS Infect Dis, 2019, 5(10): 1657-1667. DOI: 10.1021/acsinfecdis.9b00249 |
| [27] |
LIANG DY, SHA S, YI Q, et al. Hepatitis B X protein upregulates decoy receptor 3 expression via the PI3K/NF-κB pathway[J]. Cell Signal, 2019, 62: 109346. DOI: 10.1016/j.cellsig.2019.109346 |
| [28] |
WU A, CHEN H, XU C, et al. miR-203a is involved in HBx-induced inflammation by targeting Rap1a[J]. Exp Cell Res, 2016, 349(1): 191-197. DOI: 10.1016/j.yexcr.2016.10.016 |
| [29] |
|
| [30] |
LI M, HU L, ZHU F, et al. Hepatitis B virus X protein promotes renal epithelial-mesenchymal transition in human renal proximal tubule epithelial cells through the activation of NF-κB[J]. Int J Mol Med, 2016, 38(2): 513-520. DOI: 10.3892/ijmm.2016.2637 |
| [31] |
YANG Y, WANG X, ZHANG Y, et al. Hepatitis B virus X protein and proinflammatory cytokines synergize to enhance TRAIL-induced apoptosis of renal tubular cells by upregulation of DR4[J]. Int J Biochem Cell Biol, 2018, 97: 62-72. DOI: 10.1016/j.biocel.2018.02.006 |
| [32] |
LI J, BAO L, ZHA D, et al. Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways[J]. Int Immunopharmacol, 2018, 55: 9-19. DOI: 10.1016/j.intimp.2017.11.040 |
| [33] |
FENG Y, CUI Y, GAO JL, et al. Resveratrol attenuates neuronal autophagy and inflammatory injury by inhibiting the TLR4/NF-κB signaling pathway in experimental traumatic brain injury[J]. Int J Mol Med, 2016, 37(4): 921-930. DOI: 10.3892/ijmm.2016.2495 |
| [34] |
YANG YT, WANG X, ZHANG YY, et al. The histone demethylase LSD1 promotes renal inflammation by mediating TLR4 signaling in hepatitis B virus-associated glomerulonephritis[J]. Cell Death Dis, 2019, 10(4): 278. DOI: 10.1038/s41419-019-1514-4 |
| [35] |
CHEN J, LI D, LUO E. Telbivudine antagonizes TLR4 to inhibit the epithelial-to-mesenchymal transition in human proximal tubular epithelial cells in vitro[J]. Int Immunopharmacol, 2019, 74: 105683. DOI: 10.1016/j.intimp.2019.105683 |
| [36] |
HE P, ZHANG B, LIU D, et al. Hepatitis B virus x protein modulates apoptosis in NRK-52E Cells and activates Fas/FasL through the MLK3-MKK7-JNK3 signaling pathway[J]. Cell Physiol Biochem, 2016, 39(4): 1433-1443. DOI: 10.1159/000447846 |
| [37] |
FU B, JI Y, HU S, et al. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis[J]. PLoS One, 2020, 15(1): e0227532. DOI: 10.1371/journal.pone.0227532 |
| [38] |
WANG WN, WU MY, MA FZ, et al. Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis[J]. Clin Nephrol, 2016, 85(1): 21-29. http://europepmc.org/abstract/med/26636326 |
| [39] |
JIANG W, LIU T, DONG H, et al. Relationship between serum DNA replication, clinicopathological characteristics and prognosis of hepatitis B virus-associated glomerulonephritis with severe proteinuria by lamivudine plus adefovir dipivoxil combination therapy[J]. Biomed Environ Sci, 2015, 28(3): 206-213. http://d.wanfangdata.com.cn/periodical/bes201503005 |
| [40] |
KAMIMURA H, SETSU T, KIMURA N, et al. Renal impairment in chronic hepatitis B: A review[J]. Diseases, 2018, 6(2): 52. DOI: 10.3390/diseases6020052 |
| [41] |
SUN LJ, SHAN JP, CUI RL, et al. Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: A clinical review of 38 cases[J]. Int Urol Nephrol, 2017, 49(6): 1049-1056. DOI: 10.1007/s11255-017-1563-5 |
| [42] |
MAHAJAN V, D'CRUZ S, NADA R, et al. Successful use of entecavir in hepatitis B-associated membranous nephropathy[J]. J Trop Pediatr, 2018, 64(3): 249-252. DOI: 10.1093/tropej/fmx058 |
| [43] |
KATAOKA H, MOCHIZUKI T, AKIHISA T, et al. Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report[J]. Medicine (Baltimore), 2019, 98(2): e14014. DOI: 10.1097/MD.0000000000014014 |
| [44] |
FANG J, LI W, PENG X, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: A retrospective analysis[J]. Int Urol Nephrol, 2017, 49(3): 475-482. DOI: 10.1007/s11255-016-1487-5 |
DownLoad: